Marinus Pharmaceuticals (LTS:0JYL) Short-Term Debt : $13.48 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Marinus Pharmaceuticals Short-Term Debt?

Marinus Pharmaceuticals's Short-Term Debt for the quarter that ended in Sep. 2024 was $13.48 Mil.

Marinus Pharmaceuticals's quarterly Short-Term Debt declined from Mar. 2024 ($15.40 Mil) to Jun. 2024 ($11.55 Mil) but then increased from Jun. 2024 ($11.55 Mil) to Sep. 2024 ($13.48 Mil).

Marinus Pharmaceuticals's annual Short-Term Debt increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.02 Mil) and increased from Dec. 2022 ($1.02 Mil) to Dec. 2023 ($11.55 Mil).

Marinus Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Marinus Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Short-Term Debt Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1.02

11.55

Marinus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															7.70	11.55	15.40	11.55	13.48

Marinus Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Marinus Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (LTS:0JYL) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals Headlines

No Headlines